{"id":653141,"date":"2013-04-18T05:45:25","date_gmt":"2013-04-18T09:45:25","guid":{"rendered":"http:\/\/www.pehub.com\/?p=197053"},"modified":"2013-04-18T05:45:25","modified_gmt":"2013-04-18T09:45:25","slug":"allecra-therapeutics-raises-funds","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/653141","title":{"rendered":"Allecra Therapeutics Raises Funds"},"content":{"rendered":"

Edmond de Rothschild Investment Partners<\/strong> has led the 5 million euro ($6.5 million) Series A financing of Allecra Therapeutics<\/strong> with its new fund BioDiscovery 4<\/strong>. <\/p>\n

PRESS RELEASE<\/strong><\/p>\n

Edmond de Rothschild Investment Partners announces the first investment of BioDiscovery 4, its fourth fund dedicated to Life Sciences, through its participation in the Series A financing round of Allecra Therapeutics, which it co-leads with Forbion Capital Partners. EMBL Ventures is also part of the syndicate.
\nAllecra was formed in 2013 in France and Germany, as a strategic partnership between Orchid Chemicals & Pharmaceuticals Limited (Chennai, India), the founders – including Allecra’s CEO Nicholas Benedict – and the two lead investors. This Series A financing of \u20ac15 million euros will support early clinical development of two new antibiotic treatments designed to combat multi drug-resistant gram-negative bacteria.
\nOlivier Litzka, Partner at Edmond de Rothschild Investment Partners and Board Director at Allecra commented: “Allecra’s strategic partnership with Orchid is an innovative collaboration bringing together Allecra’s strong development capability with Orchid’s track record in antibiotic research and manufacturing. Allecra is supported by a Scientific Advisory Board consisting of world-renowned experts and Allecra’s Board of Directors comprises key appointments of entrepreneurs and industrialists with records of success in this area.”
\nOlivier Litzka also added: “We are glad to see Allecra become the first investment of our fund Biodiscovery 4. After our successful experience in the anti-infectives space through the investment of the BioDiscovery funds in Novexel, we are convinced that Allecra has all the major ingredients for success.”
\nNicholas Benedict, Co-Founder and CEO of Allecra added: “The formation of Allecra comes at a time when governments, non-governmental agencies and the medical community are crying out for urgent and decisive action to tackle “the epidemic of antibiotic resistance. Our mission at Allecra is to develop new treatments which overcome selected bacterial resistance and which can be used to treat patients whose infections may otherwise have disastrous consequences.”
\nAbout Edmond de Rothschild Investment Partners
\nParis-based Edmond de Rothschild Investment Partners is the private equity affiliate of the Edmond de Rothschild Group which is specialized in asset management and private banking (EUR 130bn under management, 2,900 employees and 30 offices throughout the world). Founded in 1953, the Group has been chaired since 1997 by the founder’s son, Baron Benjamin de Rothschild.
\nEdmond de Rothschild Investment Partners is dedicated to minority investments into privately-owned companies. It has currently close to \u20ac1 billion under management which is being invested primarily as life sciences venture capital and growth capital.
\nIts Life Sciences Team of eight professionals brings together over 60 years of experience in the Life Science industry and more than 100 years of private equity and venture capital experience. The team has \u20ac355 million under management through its Biodiscovery franchise.
\nBioDiscovery Funds, including BioDiscovery 4, are venture capital funds registered via the fast-track procedure. These funds are not authorized by the Autorit\u00e9 des march\u00e9s financiers and may adopt special investment rules. BioDiscovery 4, a Capital Venture Funds registered via the fast-track procedure, invests mainly in private companies, which involves specific risks such as a risk of capital loss, a discretionary management risk and a liquidity risk.
\nFor more information please visit: www.edrip.fr.
\nAbout Allecra Therapeutics
\nAllecra, established in 2013, is a biotechnology company focused on the development of novel treatments to combat multi drug-resistant bacterial infections. It is based on a strategic partnership between its founders, Orchid Chemicals and Pharmaceuticals Ltd. (Chennai, India) and its lead investors, Forbion Capital Partners and Edmond de Rothschild Investment Partners. ALLECRA’s mission is to contribute towards the global effort to combat antibiotic resistance by developing new treatments which overcome emerging resistance mechanisms, thereby saving lives of patients whose infections may otherwise be inadequately treated. ALLECRA is located in the European BioValley Life Sciences cluster, located in the Upper Rhein valley, encompassing northwest Switzerland, southeastern Germany and the Alsace Region of France.<\/p>\n

Contacts<\/p>\n

Edmond de Rothschild Investment Partners
\nOlivier Litzka
\nolivier.litzka@lcfr.fr
\n+33 1 40 17 27 46 or +33 1 40 17 27 69<\/p>\n

Allecra Therapeutics GmbH
\nNicholas Benedict, Founder & CEO
\n+41 79 592 2005
\nnmb@allecra.com <\/p>\n

The post Allecra Therapeutics Raises Funds<\/a> appeared first on peHUB<\/a>.<\/p>\n

\n<\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a>\n<\/div>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Edmond de Rothschild Investment Partners has led the 5 million euro ($6.5 million) Series A financing of Allecra Therapeutics with its new fund BioDiscovery 4. PRESS RELEASE Edmond de Rothschild Investment Partners announces the first investment of BioDiscovery 4, its fourth fund dedicated to Life Sciences, through its participation in the Series A financing round […]<\/p>\n","protected":false},"author":7999,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-653141","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/653141","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/7999"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=653141"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/653141\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=653141"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=653141"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=653141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}